Recent studies have identified a causal relationship between sarcopenia and increasing risk of HCC in European populations (Cao et al. 2024), implying that MSTN, the primary mediator of sarcopenia, is a promising biomarker candidate for HCC risk stratification. The gene discussed is MSTN; the disease is hepatocellular carcinoma.